Biotech Values

[exwannabe]

Brean has been bearish here for quite a while

And certainly it is a reasonable bet that Impact misses.

But his argument that Provenge has no effect and previous studies indicating (or trending) such are no more an artifact of crossover delaying tax. administration is somewhere between strained and complete crap.

The FDA certainly would have pointed this out in the AC briefing notes 2 years ago. They did not.

Whatever all the whackos think, the FDA stat guys certainly will do a better job than the anybody else (especially given that they have vastly more data).